JP2024508895A5 - - Google Patents
Info
- Publication number
- JP2024508895A5 JP2024508895A5 JP2023553324A JP2023553324A JP2024508895A5 JP 2024508895 A5 JP2024508895 A5 JP 2024508895A5 JP 2023553324 A JP2023553324 A JP 2023553324A JP 2023553324 A JP2023553324 A JP 2023553324A JP 2024508895 A5 JP2024508895 A5 JP 2024508895A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- ddr
- genes
- gene products
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2103080.4A GB202103080D0 (en) | 2021-03-04 | 2021-03-04 | Cancer biomarkers |
| GB2103080.4 | 2021-03-04 | ||
| PCT/IB2022/051906 WO2022185260A1 (en) | 2021-03-04 | 2022-03-04 | Biomarkers for cancer therapy using mdm2 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024508895A JP2024508895A (ja) | 2024-02-28 |
| JP2024508895A5 true JP2024508895A5 (https=) | 2025-03-07 |
Family
ID=75339986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023553324A Pending JP2024508895A (ja) | 2021-03-04 | 2022-03-04 | Ｍｄｍ２アンタゴニストを用いた癌療法のためのバイオマーカー |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240293364A1 (https=) |
| EP (1) | EP4301875A1 (https=) |
| JP (1) | JP2024508895A (https=) |
| KR (1) | KR20230150285A (https=) |
| CN (1) | CN117295825A (https=) |
| AU (1) | AU2022230312A1 (https=) |
| BR (1) | BR112023017572A2 (https=) |
| CA (1) | CA3205532A1 (https=) |
| GB (1) | GB202103080D0 (https=) |
| IL (1) | IL304375A (https=) |
| MX (1) | MX2023010258A (https=) |
| TW (1) | TW202302087A (https=) |
| WO (1) | WO2022185260A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| WO2023134707A1 (en) * | 2022-01-11 | 2023-07-20 | Ascentage Pharma (Suzhou) Co., Ltd. | Methods for treating aml-mrc and mds |
| WO2024243078A1 (en) * | 2023-05-19 | 2024-11-28 | Leapfrog Bio, Inc. | Hsp90 inhibitors for the treatment of cancer |
| TW202540077A (zh) * | 2023-11-16 | 2025-10-16 | 日商大塚製藥股份有限公司 | 具有抗癌活性之ｍｄｍ２－ｐ５３交互作用的異吲哚啉酮抑制劑的中間體的製造方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| EP0951541B1 (en) | 1995-07-31 | 2005-11-30 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| UA107814C2 (uk) | 2009-11-12 | 2015-02-25 | Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган | Спірооксіндольні антагоністи мdм2 |
| WO2011058367A2 (en) * | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| UY34591A (es) | 2012-01-26 | 2013-09-02 | Novartis Ag | Compuestos de imidazopirrolidinona |
| EP2958893B1 (en) | 2013-02-21 | 2017-05-03 | F. Hoffmann-La Roche AG | Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide |
| CN105358530A (zh) | 2013-06-10 | 2016-02-24 | 美国安进公司 | 制备mdm2抑制剂的方法及其结晶形式 |
| BR112015029976A2 (pt) | 2013-06-24 | 2017-07-25 | Hoffmann La Roche | formulação farmacêutica, formulação liofilizada farmacêutica e preparações novas, métodos e usos |
| KR20220136454A (ko) | 2013-09-04 | 2022-10-07 | 다이이찌 산쿄 가부시키가이샤 | 스피로옥시인돌 유도체의 제조 방법 |
| US9657351B2 (en) | 2013-12-06 | 2017-05-23 | Hoffman-La Roche Inc. | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist |
| BR122022015241B1 (pt) | 2013-12-20 | 2023-09-26 | Astex Therapeutics Limited | Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i) |
| CA2945527C (en) | 2014-04-17 | 2022-05-17 | The Regents Of The University Of Michigan | Mdm2 inhibitors and therapeutic methods using the same |
| JP2017532959A (ja) * | 2014-10-09 | 2017-11-09 | 第一三共株式会社 | Ｍｄｍ２阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| SG11201808728QA (en) | 2016-04-06 | 2018-11-29 | Univ Michigan Regents | Mdm2 protein degraders |
| US10759808B2 (en) | 2016-04-06 | 2020-09-01 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| WO2017205786A1 (en) | 2016-05-27 | 2017-11-30 | Aileron Therapeutics, Inc. | Cell permeable peptidomimetic macrocycles |
| GB201704965D0 (en) * | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| CA3050645A1 (en) * | 2018-07-27 | 2020-01-27 | Ottawa Hospital Research Institute | Treatment of acute myeloid leukemia |
| EP3814525A4 (en) * | 2019-02-24 | 2022-04-13 | Ascentage Pharma (Suzhou) Co., Ltd. | TREATMENT METHODS AND BIOMARKERS FOR MDM2 INHIBITORS |
| GB201919219D0 (en) * | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
-
2021
- 2021-03-04 GB GBGB2103080.4A patent/GB202103080D0/en not_active Ceased
-
2022
- 2022-03-04 US US18/548,522 patent/US20240293364A1/en active Pending
- 2022-03-04 BR BR112023017572A patent/BR112023017572A2/pt unknown
- 2022-03-04 KR KR1020237028389A patent/KR20230150285A/ko active Pending
- 2022-03-04 WO PCT/IB2022/051906 patent/WO2022185260A1/en not_active Ceased
- 2022-03-04 MX MX2023010258A patent/MX2023010258A/es unknown
- 2022-03-04 CN CN202280017371.3A patent/CN117295825A/zh active Pending
- 2022-03-04 AU AU2022230312A patent/AU2022230312A1/en active Pending
- 2022-03-04 CA CA3205532A patent/CA3205532A1/en active Pending
- 2022-03-04 JP JP2023553324A patent/JP2024508895A/ja active Pending
- 2022-03-04 EP EP22707524.9A patent/EP4301875A1/en active Pending
- 2022-03-04 TW TW111108020A patent/TW202302087A/zh unknown
-
2023
- 2023-07-10 IL IL304375A patent/IL304375A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024508895A5 (https=) | ||
| JP2023508165A5 (https=) | ||
| ES2705950T3 (es) | Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib | |
| Wasko et al. | Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer | |
| US12099068B2 (en) | Biomarkers for graft-versus-host disease | |
| EP1934377B1 (en) | Methods for identifying biomarkers useful in diagnosis of biological states | |
| JP5797288B2 (ja) | Ｖｅｇｆ多型および抗脈管形成治療 | |
| ES2691213T3 (es) | Tratamiento de cáncer | |
| US12553090B2 (en) | Molecular predictors of patient response to radiotherapy treatment | |
| US12325880B2 (en) | Identification of PDE3 modulator responsive cancers | |
| JP2011505145A5 (https=) | ||
| JP2012514460A (ja) | ボルテゾミブを用いた多発性骨髄腫患者における生存率の予測 | |
| Pisani et al. | Proteomic insights on the metabolism in inflammatory bowel disease | |
| JP2015502137A5 (https=) | ||
| KR101997320B1 (ko) | 항암 치료 내성 판단 방법 및 상기 방법에 사용되는 조성물 | |
| WO2019173712A1 (en) | Addressing treatments for glioblastoma | |
| WO2014072086A1 (en) | Biomarkers for prognosis of lung cancer | |
| Jiang et al. | Molecular analysis of inflammatory bowel disease: clinically useful tools for diagnosis, response prediction, and monitoring of targeted therapy | |
| US20150218242A1 (en) | TIF1-Gamma for Treating and Diagnosing Inflammatory Diseases | |
| JP2019190976A (ja) | スティル病と敗血症との鑑別用バイオマーカー | |
| US20070042364A1 (en) | Target genes for inflammatory bowel disease | |
| Siddiqui et al. | Racial differences in serum chemokines in prostate cancer patients | |
| KR20230060494A (ko) | 말초 t세포 림프종 예후 예측용 신규 바이오마커 및 이의 용도 | |
| ASAD et al. | V enereologica | |
| CN117479957A (zh) | 用于包含血管生成抑制剂的疗法的生物标志物 |